Case Series Highlights Bacillus Cereus Risk in Patients With AML, Neutropenia
March 12th 2024Introducing ciprofloxacin to their institution’s empiric antimicrobial regimen for patients with AML and prolonged or recurrent neutropenic fevers appeared to reduce the risk of Bacillus cereus infection.
Read More
ELN Risk Category, MRD Status Predictive of Relapse in Patients With AML
January 29th 2024The study may help explain why some patients are more prone to relapse following a complete response to induction therapy, as indicated by measurable residual disease (MRD) status and 2017 European LeukemiaNet (ELN) criteria.
Read More
Increased Fatigue Associated With Greater Risk of Mortality Among Patients With AML, ALL, MDS
January 27th 2024The findings suggest patient-reported outcomes—namely fatigue—may be helpful in identifying patients at a higher risk of death and other adverse outcomes but warrant further research.
Read More
alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden
December 22nd 2023Those with chronic graft-versus-host-disease who have received allogeneic hematopoietic stem cell transplant (alloHSCT) may experience enhanced graft-versus-leukemia effects, thus producing a lower relapse rate in acute myeloid leukemia.
Read More
High Disease Burden at Acute Leukemia Diagnosis More Common in Black Children, Study Finds
November 3rd 2023A study evaluating disparities among children with acute leukemia found that Black children are more likely to present with higher disease burden at diagnosis compared with non-Hispanic White children.
Read More
AML-Specific Early Mortality Risk Indices May Increase Accuracy of Care Quality Measurements
September 8th 2023A study found acute myeloid leukemia (AML) salvage therapy was independently associated with early mortality compared with frontline therapy, suggesting that algorithms measuring quality of care should incorporate risk mortality indices that factor in disease characteristics and treatment status.
Read More